Engineered immune cells take on recurrent brain tumors
NCT ID NCT07481721
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests a new treatment for people whose malignant glioma (a type of brain cancer) has come back. The therapy uses the patient's own immune cells, modified to recognize and attack the cancer while also blocking a tumor defense mechanism. The study will enroll 24 adults to check safety and see if it helps control tumor growth.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT MALIGNANT GLIOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Beijing, Beijing Municipality, 100021, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Targeted drug aims to shrink recurrent brain tumors by blocking key growth enzyme
- Immunotherapy drug nivolumab tested in young brain cancer patients
- Targeted drug shows promise for kids with tough cancers
- New hope for kids with Hard-to-Treat cancers: targeted drug shows promise
- Immune drug takes on recurrent brain tumors in small pilot study
- 1000 brain tumor Patients' records reviewed to see what worked